AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25479227
Drug: 940nm diode
RxNorm normalized name: Dioderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 940nm diode laser treatment
Trial: 25479227
Drug: Bipolar radiofrequency
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bipolar radiofrequency therapy
Trial: 24669646
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 0.2 mg + I/V fentanyl 2 microg/Kg
Trial: 24669646
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo + I/V fentanyl 2 microg/Kg
Trial: 16188207
Drug: Flax oil
RxNorm normalized name: Flax oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax oil (60 g)
Trial: 16188207
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (60 g)
Trial: 12816171
Drug: High-dose lisinopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose lisinopril (32.5-35.0 mg/day)
Trial: 31421664
Drug: Shallot (3g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shallot (3g per day) and cetirizine (10 mg once daily)
Trial: 31421664
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg once daily) and placebo capsules
Trial: 29183775
Drug: Isoflavone pills
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone pills (60 mg genistein, 60 mg daidzein, 16.6 mg glycitein)
Trial: 14575666
Drug: Bilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral injection of hypertonic saline (two injections)
Trial: 14575666
Drug: Unilateral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral injection of hypertonic saline (one injection)
Trial: 26809813
Drug: Gatifloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (10 mg/kg per day for 7 days)
Trial: 26809813
Drug: Ceftriaxone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (60 mg/kg up to 2 g per day for 7 days)
Trial: 8774269
Drug: Creatine supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplement (5 g of creatine plus 1 g of glucose)
Trial: 8774269
Drug: Glucose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose placebo (6 g of glucose)
Trial: 1377412
Drug: DDAVP infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP infusion
Trial: 27304196
Drug: Vorapaxar (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar (2.5 mg q.d. for 7 days)
Trial: 27304196
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg q.d. for 7 days)
Trial: 27304196
Drug: Vorapaxar +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar + Aspirin (for 7 days)
Trial: 27304196
Drug: Aspirin (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (for 7 days)
Trial: 24699310
Drug: Sativex(®) low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex(®) low dose (5.4mg THC)
Trial: 24699310
Drug: Sativex(®) high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex(®) high dose (21.6mg THC)
Trial: 23896849
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation with supplemental Internet-based homework (10 weeks of weekly group sessions and daily online cognitive exercises)
Trial: 20843504
Drug: Diclectin (doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation)
Trial: 8737752
Drug: Spirapril 3
RxNorm normalized name: spirapril 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril 3 mg and 6 mg
Trial: 1331494
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g kg‐1 body mass)
Trial: 23680589
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) iron (Iron Sucrose 200 mg, once a week for 5 weeks)
Trial: 23680589
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) iron (ferrous sulfate 200 mg TID for 8 weeks)
Trial: 21642644
Drug: Phenylephrine (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (100-200 µg)
Trial: 21642644
Drug: Ephedrine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (5-20 mg)
Trial: 16719616
Drug: Applied tension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied tension technique (treatment condition)
Trial: 9209247
Drug: Oral cotinine
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cotinine treatment (0.25 mg/kg twice a day)
Trial: 9209247
Drug: Low-dose cotinine-d4
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cotinine-d4 infusion
Trial: 8080160
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution containing acetate
Trial: 8080160
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution without acetate
Trial: 29321067
Drug: Mechanical Oral
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical Oral Hygiene (MOH) only
Trial: 24188861
Drug: Helping Alliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helping Alliance Questionnaire I (measured twice, middle and late during treatment)
Trial: 20530276
Drug: ixabepilone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ixabepilone (40 mg/m² intravenously on day 1) plus capecitabine (2,000 mg/m² orally on days 1 through 14)
Trial: 20530276
Drug: capecitabine alone
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine alone (2,500 mg/m² on the same schedule)
Trial: 16633890
Drug: Budesonide (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Dosage Form A, 3 mg)
Trial: 16633890
Drug: Budesonide (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Dosage Form A, 9 mg)
Trial: 16633890
Drug: Budesonide (Dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Dosage Form B, 9 mg)
Trial: 10663279
Drug: Ranitidine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine alone (150 mg preoperatively per os and 50 mg intravenously postoperatively)
Trial: 10663279
Drug: Ranitidine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine combined with dobutamine (150 mg preoperatively per os and 50 mg intravenously postoperatively + dobutamine 4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Trial: 10663279
Drug: Dobutamine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine alone (4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Trial: 8797464
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (1 g/kg body weight/day for 2 days, total dose 2.0 g/kg body weight)
Trial: 15209626
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (IFN-alpha-2b + hepatitis B vaccine)
Trial: 15209626
Drug: IFN-alpha-2b monotherapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-alpha-2b monotherapy
Trial: 11324727
Drug: Twice-daily 3
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice-daily 3 MU of IFN beta (group A)
Trial: 11324727
Drug: Once-daily 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily 6 MU of IFN-beta (group B)
Trial: 3285170
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg. kg‐1
Trial: 30690691
Drug: VEL-091604 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEL-091604 cream applied 2 times daily for 2 weeks
Trial: 30690691
Drug: VEL-091604 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEL-091604 cream in atopic dermatitis subjects
Trial: 26462570
Drug: Short-term meditation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term meditation (MG) with positive suggestions
Trial: 26462570
Drug: Short-term meditation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term meditation (MG) with negative suggestions
Trial: 22592214
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (0.9% NaCl)
Trial: 19878508
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg weekly for 4 weeks
Trial: 11828040
Drug: Logistic regression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Logistic regression model with symptoms, free running test, and methacholine inhalation challenge results
Trial: 10036612
Drug: Haloperidol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1.0 mg
Trial: 10036612
Drug: Haloperidol 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2.0 mg
Trial: 6944708
Drug: Reserpine 0.5
RxNorm normalized name: reserpine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserpine 0.5 mg i.m.
Trial: 6944708
Drug: Haloperidol 0.5
RxNorm normalized name: haloperidol 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 0.5 mg i.m.
Trial: 31713262
Drug: Extended sensory
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Extended sensory intervention (SI) with additional weekly visits from a sensory support therapist (SST)
Trial: 22571890
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (statistical treatment guidelines for AAA)
Trial: 12418673
Drug: Liquid DTP/PRP-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid DTP/PRP-T formulation
Trial: 12418673
Drug: Liquid DTP/PRP-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid DTP/PRP-T formulation (Part 2)
Trial: 12418673
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of PRP-T/DTP
Trial: 31855498
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements (vitamins A, C, and E; carotenoids; coenzyme Q10) before and during treatment
Trial: 31855498
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 use before and during chemotherapy
Trial: 31855498
Drug: Iron use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron use during chemotherapy
Trial: 28416405
Drug: SLEEP Inventory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLEEP Inventory (Sex, Left heart failure, ESS, Enlarged neck, weight [in Pounds], Insulin resistance/diabetes, and National Institutes of Health Stroke Scale)
Trial: 23381494
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone furoate (MF) for 6 weeks
Trial: 10861916
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 3.7 mg/day)
Trial: 10861916
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic agents (historical control)
Trial: 2874825
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 or 40 mg)
Trial: 28436580
Drug: Rescue antenatal
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue antenatal steroids (AS)
Trial: 24495273
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride orally disintegrating tablet (ODT) with 10 mg of ammonium glycyrrhizinate
Trial: 17563023
Drug: Sequential counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential counseling (addressing a new behavior every 6 months)
Trial: 17563023
Drug: Sequential counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential counseling
Trial: 12719667
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (group A)
Trial: 12719667
Drug: Topical norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical norfloxacin (group B)
Trial: 11035829
Drug: LCPUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPUFA supplementation (fat supplement supplying 26% as fatty acids including DHA, 8%)
Trial: 1406879
Drug: Deferoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (100 mg/kg/day for 72 hours)
Trial: 3899674
Drug: RU 28318
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 28318 100 mg (9 alpha‐FHC ingestion)
Trial: 3899674
Drug: RU 28318
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 28318 200 mg (aldosterone infusion)
Trial: 3899674
Drug: RU 28318
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 28318 100 mg (furosemide ingestion)
Trial: 3899674
Drug: RU 28318
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 28318 300 mg (furosemide ingestion)
Trial: 3899674
Drug: Spironolactone (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (identical doses to RU 28318)
Trial: 12839693
Drug: rhIL-11 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 (25 microg/kg body weight, subcutaneously once daily for 7 to 14 days)
Trial: 30663077
Drug: Pregabalin 225
RxNorm normalized name: pregabalin 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 225 mg twice daily for 12 weeks
Trial: 28935772
Drug: Carfilzomib in
RxNorm normalized name: carfilzomib Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib in combination with lenalidomide and dexamethasone (CRd)
Trial: 29915914
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin use
Trial: 22182951
Drug: Cranial OMM
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial OMM augmentation technique
Trial: 22182951
Drug: Cranial OMM
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial OMM and sham therapy
Trial: 11305826
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I - 20 mg lidocaine plus 25 microg fentanyl
Trial: 11305826
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II - 20 mg lidocaine plus 10 microg sufentanil
Trial: 11305826
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III - 10 mg lidocaine plus 10 microg sufentanil
Trial: 31906766
Drug: Gait training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gait training with the Biodex Gait Trainer 3 (a treadmill integrated with music therapy)
Trial: 29563779
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (500 mL·d‐1 for 1 month)
Trial: 29563779
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (500 mL·d‐1 for 3 months)
Trial: 25528251
Drug: no local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no local hemostatic agents
Trial: 18849063
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intramuscular (IM) dimenhydrinate
Trial: 18849063
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL IM saline solution (placebo)
Trial: 11230840
Drug: Omapatrilat (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omapatrilat (high-dose groups)
Trial: 8565032
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core 30 mg
Trial: 8565032
Drug: Nifedipine coat-core
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine coat-core 60 mg
Trial: 2350875
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg intravenously)
Trial: 24277399
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding group
Trial: 18499623
Drug: PERI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PERI group receiving intraoperative and postoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Trial: 18499623
Drug: INTRA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTRA group receiving intraoperative ketamine (2 microg x kg(‐1) x min(‐1) after a 0.5 mg/kg bolus)
Trial: 16542203
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg day(-1) and Olanzapine 15 mg day(-1) coadministration (LTG + OLZ group)
Trial: 16542203
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg day(-1) with placebo (LTG group)
Trial: 16542203
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Olanzapine 15 mg day(-1) (OLZ group)
Trial: 12716329
Drug: Guided Tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Tissue Regeneration (GTR) - ePTFE membranes (Gore‐Tex W.L. Gore and Associates, Flagstaff, AZ, USA)
Trial: 11113227
Drug: Cladribine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (0.7 mg/kg and 2.1 mg/kg)
Trial: 9762661
Drug: Virus-specific oligoclonal
RxNorm normalized name: rubella virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virus-specific oligoclonal IgG antibodies
Trial: 2841177
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Load
Trial: 30511958
Drug: Twister wrap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twister wrap orthosis (TWO) in addition to conventional physical therapy and ankle foot orthosis (AFO)
Trial: 30511958
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy and ankle foot orthosis (AFO)
Trial: 25331468
Drug: Allitridi capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allitridi capsules (120 mg/day)
Trial: 21174182
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic approach (MMA) including paravertebral blocks with 0.5% ropivacaine, celecoxib (400 mg po prior to surgery and 200 mg po bid for seven days), and ketamine (10 mg iv)
Trial: 21174182
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic approach (MMA)
Trial: 7817261
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for exophytic warts or clinical symptoms (n = 55)
Trial: 3061032
Drug: Indoramin (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (initial dose 50 mg/d)
Trial: 3061032
Drug: Propranolol (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (initial dose 80 mg/d)
Trial: 24321138
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust exposure (PM1300 μg/m(3))
Trial: 24321138
Drug: Filtered air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtered air exposure (PM12 μg/m(3))
Trial: 16647301
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) at doses of 50, 75, and 100 mg/day
Trial: 16647301
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from TPM and substitution with older antiepileptic drugs
Trial: 14521743
Drug: Naphtoquine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naphtoquine (1,000 mg single daily dosage for one day)